Download or read book The Oncogenomics Handbook written by William J. LaRochelle and published by Springer Science & Business Media. This book was released on 2007-11-09 with total page 745 pages. Available in PDF, EPUB and Kindle. Book excerpt: An integrated overview of cancer drug discovery and development from the bench to the clinic, showing with broad strokes and representative examples the drug development process as a network of linked components leading from the discovered target to the ultimate therapeutic product. Following a systems biology approach, the authors explain genomic databases and how to discover oncological targets from them, how then to advance from the gene and transcript to the level of protein biochemistry, how next to move from the chemical realm to that of the living cell and, ultimately, pursue animal modeling and clinical development. Emerging cancer therapeutics including Ritux an, Erbitux, Gleevec Herceptin, Avastin, ABX-EGF, Velcade, Kepivance, Iressa, Tarceva, and Zevalin are addressed. Highlights include cancer genomics, pharmacogenomics, transcriptomics, gene expression analysis, proteomic and enzymatic cancer profiling technologies, and cellular and animal approaches to cancer target validation.
Download or read book Oncogenomics written by Charles Brenner and published by John Wiley & Sons. This book was released on 2004-11-19 with total page 411 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book aims to assemble the only available rigorous, yet broadly accessible introduction to this new and exciting field. Oncogenomics: Molecular Approaches to Cancer is approachable by basic scientists, practitioners, and other health professionals required to familiarize themselves with the tremendous impact of genomics and proteomics on cancer research. Clearly written chapters offer reviews of state of the art topics such as molecular classification, early detection, SNPs in cancer, data mining, tissue microarrays, protein and antibody arrays, and drug targets.
Download or read book Infections Causing Human Cancer written by Harald zur Hausen and published by John Wiley & Sons. This book was released on 2007-09-24 with total page 531 pages. Available in PDF, EPUB and Kindle. Book excerpt: Infections must be thought as one of the most important, if not the most important, risk factors for cancer development in humans. Approximately 15-20% of all cases of cancer around the world are caused by viruses. The establishment of a causal relationship between the presence of specific infective agents and certain types of human cancer represents a key step in the development of novel therapeutic and preventive strategies. In this book, Professor zur Hausen (Nobel Prize in Physiology/Medicine 2008) provides a thorough and comprehensive overview on carcinogenic infective agents -- viruses, bacteria, parasites and protozoons -- as well as their corresponding transforming capacities and mechanisms. The result is an invaluable and instructive reference for all oncologists, microbiologists and molecular biologists working in the area of infections and cancer. The author was among the first scientists to reveal the cervical cancer-inducing mechanisms of human papilloma viruses and isolated HPV16 and HPV18, and, as early as 1976, published the hypothesis that wart viruses play a role in the development of this type of cancer.
Download or read book Bone Metastasis written by Gurmit Singh and published by Springer Science & Business Media. This book was released on 2007-10-28 with total page 343 pages. Available in PDF, EPUB and Kindle. Book excerpt: A state-of-the-art review of the molecular underpinnings of bone-seeking cancers, current treatment approaches for them, and future therapeutic strategies. The authors illuminate the role of various autocrine, paracrine, and immunological factors involved in the progression and establishment of bone metastases, highlighting the physiological processes that lead to bone degradation, pain, angiogenesis, and dysregulation of bone turnover. They also discuss the various strategies that appear to have promise and are currently deployed in treatment or are at the experimental stage.
Download or read book Protein Tyrosine Kinases written by Doriano Fabbro and published by Springer Science & Business Media. This book was released on 2007-11-13 with total page 599 pages. Available in PDF, EPUB and Kindle. Book excerpt: Leading researchers, from the Novartis group that pioneered Gleevec/GlivecTM and around the world, comprehensively survey the state of the art in the drug discovery processes (bio- and chemoinformatics, structural biology, profiling, generation of resistance, etc.) aimed at generating PTK inhibitors for the treatment of various diseases, including cancer. Highlights include a discussion of the rationale and the progress made towards generating "selective" low molecular-weight kinase inhibitors; an analysis of the normal function, role in disease, and application of platelet-derived growth factor antagonists; and a summary of the factors involved in successful structure-based drug design. Additional chapters address the advantages and disadvantages of in vivo preclinical models for testing protein kinase inhibitors with antitumor activity and the utility of different methods in the drug discovery and development process for determining "on-target" vs "off-target" effects of kinase inhibitors.
Download or read book Cancer Drug Resistance written by Beverly A. Teicher and published by Springer Science & Business Media. This book was released on 2007-11-09 with total page 611 pages. Available in PDF, EPUB and Kindle. Book excerpt: Leading experts summarize and synthesize the latest discoveries concerning the changes that occur in tumor cells as they develop resistance to anticancer drugs, and suggest new approaches to preventing and overcoming it. The authors review physiological resistance based upon tumor architecture, cellular resistance based on drug transport, epigenetic changes that neutralize or bypass drug cytotoxicity, and genetic changes that alter drug target molecules by decreasing or eliminating drug binding and efficacy. Highlights include new insights into resistance to antiangiogenic therapies, oncogenes and tumor suppressor genes in therapeutic resistance, cancer stem cells, and the development of more effective therapies. There are also new findings on tumor immune escape mechanisms, gene amplification in drug resistance, the molecular determinants of multidrug resistance, and resistance to taxanes and Herceptin.
Download or read book Immunotherapy of Cancer written by Mary L. Disis and published by Springer Science & Business Media. This book was released on 2007-10-28 with total page 517 pages. Available in PDF, EPUB and Kindle. Book excerpt: Expert bench and clinical scientists join forces to concurrently review both the state-of-the-art in tumor immunology and its clinical translation into promising practical treatments. The authors explain in each chapter the scientific basis behind such therapeutic agents as monoclonal antibodies, cytokines, vaccines, and T-cells, and illustrate their clinical manipulation to combat cancer. Additional chapters address statistical analysis-both of clinical trials and assay evaluations-methods for the discovery of antigens, adoptive T cell therapy, and adaptive and innate immunity. The challenges in clinical trial design, the need for biomarkers of response-such as novel imaging techniques and immunologic monitoring-and the new advances and directions in cancer immunotherapy are also fully examined.
Download or read book Antiangiogenic Agents in Cancer Therapy written by Beverly A. Teicher and published by Springer Science & Business Media. This book was released on 2008-01-08 with total page 585 pages. Available in PDF, EPUB and Kindle. Book excerpt: This volume represents a compendium of scientific findings and approaches to the study of angiogenesis in cancer. The second edition of Antiangiogenic Agents in Cancer Therapy is intended to give a current perspective on the state-of-the-art of angiogenensis and therapy directed at this process. Antiangiogenesis is a dynamic and evolving field in oncology. New therapeutic targets continue to emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials. Optimizing the therapeutic potential of antiangiogenic agents in combination with the other therapies in the armamentarium to fight cancer will be an on-going challenge.
Download or read book Death Receptors in Cancer Therapy written by Wafik S. El-Deiry and published by Springer Science & Business Media. This book was released on 2007-11-15 with total page 374 pages. Available in PDF, EPUB and Kindle. Book excerpt: An in depth review of our latest understanding of the molecular events that regulate cell death and those molecules that provide targets for developing agonists or antagonists to modulate death signaling for therapeutic purposes. The authors focus on the extrinsic system of death receptors, their regulation and function, and their abnormalities in cancer. Topics of particular interest include resistance to apoptosis, TRAIL signaling, death receptors in embryonic development, mechanisms of caspase activation, and death receptor mutations in cancer. Additional chapters address death signaling in melanoma, synthetic retinoids and death receptors, the role of p53 in death receptor regulation, immune suppression of cancer, and combination therapy with death ligands.
Download or read book Regional Cancer Therapy written by Peter M. Schlag and published by Springer Science & Business Media. This book was released on 2007-10-20 with total page 455 pages. Available in PDF, EPUB and Kindle. Book excerpt: This volume provides a biological and pharmacological background for regional cancer therapy, strategies and techniques for regional therapies, and specific indications and results for different tumor entities. Clinical trial concepts and detailed treatment protocols are also presented. This book is essential reading for researchers and clinicians engaged in seeking advanced therapeutic options for cancer patients worldwide.
Download or read book Histone Deacetylases written by Eric Verdin and published by Springer Science & Business Media. This book was released on 2007-11-06 with total page 349 pages. Available in PDF, EPUB and Kindle. Book excerpt: A panel of leading investigators summarizes and synthesizes the new discoveries in the rapidly evolving field of histone acetylation as a key regulatory mechanism for gene expression. The authors describe what has been learned about these proteins, including the identification of the enzymes, the elucidation of the enzymatic mechanisms of action, and the identification of their substrates and their partners. They also review the structures that have been solved for a number of enzymes-both alone and in complex with small molecule inhibitors-and the biological roles of the several histone deacetylases (HDAC) genes that have been knocked out in mice.
Download or read book Molecular Targeting in Oncology written by Howard L. Kaufman and published by Springer Science & Business Media. This book was released on 2007-12-26 with total page 719 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book presents an overview of the development of targeted therapies for the treatment of cancer with an emphasis on clinical application. The volume covers the complexity of the rapidly developing area of targeted therapies for the treatment of patients with cancer. It is structured in a way so readers may begin with chapters that most interest them and work through the rest of the chapters in the order of their choice.
Download or read book Deoxynucleoside Analogs in Cancer Therapy written by Godefridus J Peters and published by Springer Science & Business Media. This book was released on 2007-11-07 with total page 482 pages. Available in PDF, EPUB and Kindle. Book excerpt: Successful cancer chemotherapy relies heavily on the application of various deoxynucleoside analogs. Since the very beginning of modern cancer chemotherapy, a number of antimetabolites have been introduced into the clinic and subsequently applied widely for the treatment of many malignancies, both solid tumors and hematological disorders. In the latter diseases, cytarabine has been the mainstay of treatment of acute myeloid leukemia. Although many novel compounds were synthesized in the 1980s and 1990s, no real improvement was made. However, novel technology is now capable of elucidating the molecular basis of several inborn errors as well as some specific malignancies. This has enabled the synthesis of several deoxynucleoside analogs that could be applied for specific malignancies, such as pentostatin and subsequently chlorodeoxyadenosine (cladribine) for the treatment of hairy cell leukemia. Already in the early stage of deoxynucleoside analog development, it was recognized that several of these compounds were very effective in the treatment of various viral infections, such as for the treatment of herpes infections. This formed the basis initially for the design of azidothymidine and subsequently many other analogs, which are currently successfully used for the treatment of HIV infections. As a spin-off of these research lines, some compounds not eligible for development as antiviral agents appeared to be very potent anticancer agents. The classical example is gemcitabine, now one of the most widely applied deoxynucleoside analogs, used for the (combination) treatment of non-small cell lung cancer, pancreatic cancer, bladder cancer, and ovarian cancer.
Download or read book Cytokines in the Genesis and Treatment of Cancer written by Michael A. Caligiuri and published by Springer Science & Business Media. This book was released on 2007-09-19 with total page 483 pages. Available in PDF, EPUB and Kindle. Book excerpt: Cytokines in the Genesis and Treatment of Cancer provides a comprehensive picture of the dual role of host responses in promoting and inhibiting tumor progression. This volume represents an important investigation into the emerging intersection of cancer biology and cancer immunology. The book brings together an impressive array of internationally distinguished investigators who are devoted to the study of cytokines and cancer.
Download or read book Combination Cancer Therapy written by Gary K. Schwartz and published by Springer Science & Business Media. This book was released on 2007-10-27 with total page 289 pages. Available in PDF, EPUB and Kindle. Book excerpt: Expert physician-scientists and clinicians review those combinations of novel target agents classic chemotherapies that hold the most promise for the future of medical oncology, and detail their optimal sequence, pharmacokinetic interactions, and interaction with downstream cellular signals. The combinations run the gamut of targeted therapies against cell surface receptors (EGF-R and HER2), the cell cycle (the CDKs), signal transduction events (PKC and NF-kB), apoptosis (bcl-2), as well as focused therapies in ovarian cancer, hematologic diseases, and breast cancer. The authors emphasize novel translational approaches that are rapidly moving from the laboratory bench top to the patient's bedside for the future treatments in cancer therapy.
Download or read book Gene Therapy for Cancer written by Kelly K. Hunt and published by Springer Science & Business Media. This book was released on 2007-10-26 with total page 469 pages. Available in PDF, EPUB and Kindle. Book excerpt: The three sections of this volume present currently available cancer gene therapy techniques. Part I describes the various aspects of gene delivery. In Part II, the contributors discuss strategies and targets for the treatment of cancer. Finally, in Part III, experts discuss the difficulties inherent in bringing gene therapy treatment for cancer to the clinic. This book will prove valuable as the volume of preclinical and clinical data continues to increase.
Download or read book Biomarkers in Breast Cancer written by Giampietro Gasparini and published by Springer Science & Business Media. This book was released on 2008-01-17 with total page 335 pages. Available in PDF, EPUB and Kindle. Book excerpt: Expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers and examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines for the validation studies of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers.
